Apogee Therapeutics Newsroom

Apogee Therapeutics Director Mark McKenna Acquires $990,775 in Stock

InvestingDec 16 06:14 ET

Express News | Guggenheim Reiterates Buy on Apogee Therapeuticsto Buy

BenzingaDec 12 10:43 ET

Apogee Therapeutics Advances Phase 1 Clinical Trial for APG333 in Asthma and COPD With Interim Data Expected in 2H 2025

Quiver QuantitativeDec 10 07:12 ET

Express News | Apogee Therapeutics Inc - Interim Data From Phase 1 Trial Expected in 2H 2025

ReutersDec 10 07:00 ET

Express News | Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of Apg333, Its Novel Half-Life Extended Tslp Antibody for the Treatment of Respiratory and Broader I&I Conditions

ReutersDec 10 07:00 ET

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, Its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions

GlobeNewswireDec 10 07:00 ET

Insider Sale: Chief Medical Officer of $APGE (APGE) Sells 6,665 Shares

Quiver QuantitativeDec 6 20:17 ET

TD Cowen Maintains Apogee Therapeutics(APGE.US) With Buy Rating

Moomoo NewsDec 5 10:33 ET · Ratings

Promising Potential of Apogee Therapeutics: A Buy Rating Backed by Innovative Pipeline and Strategic Approach

TipRanksDec 5 10:27 ET · Ratings

TD Cowen Sticks to Its Buy Rating for Apogee Therapeutics, Inc. (APGE)

TipRanksDec 5 10:17 ET · Ratings

Apogee Therapeutics Price Target Raised to $110.00/Share From $95.00 by Guggenheim

Dow JonesDec 3 11:42 ET · Ratings

CCORF Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $89

Moomoo NewsDec 3 07:33 ET · Ratings

Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics, Inc. (APGE) and TransMedics Group (TMDX)

TipRanksDec 3 07:01 ET · Ratings

Express News | Apogee Therapeutics Inc : Jefferies Raises Target Price to $82 From $75

ReutersDec 3 02:16 ET

Apogee Therapeutics Is Maintained at Outperform by Wedbush

Dow JonesDec 2 10:47 ET · Ratings

Express News | Apogee Therapeutics Inc : Wedbush Raises Target Price to $90 From $87

ReutersDec 2 06:56 ET

Apogee Therapeutics Plans to Take Combination Approach to AD

TipRanksDec 2 06:15 ET

Apogee Therapeutics Plans To Highlight Updates From Across Its Pipeline During Virtual R&D Day

BenzingaDec 2 06:04 ET

Guggenheim Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $110

Moomoo NewsNov 27 07:33 ET · Ratings

Express News | Apogee Therapeutics Inc : Guggenheim Raises Target Price to $110 From $95

ReutersNov 27 06:19 ET